Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2018 /
Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer

14th - 18th Apr 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.04.18
Views: 1087
Rating:

Dr Arjun Balar - NYU Langone Medical Center, New York, USA

Dr Balar speaks with ecancer at AACR 2018 about the early results from patients treated with combined immunotherapies targeting PD-1 and CTLA-4.

He describes the patient cohort recruited so far by disease stage and biomarker expression, and the tolerability of combined checkpoint therapy.

Further phase III trials, including the DANUBE study, are ongoing.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation